How can CV outcomes trials in T2D guide clinical practice?

An expert panel offers practical insights.

This content has been independently produced by ADG, made possible through sponsorship from Eli Lilly.

Cardiovascular disease is the leading cause of death in people with type 2 diabetes, so addressing cardiovascular risk is a vital part of diabetes care.

But how do you translate data from cardiovascular outcomes trials into real-world patient care, particularly when each trial has different characteristics and different patient populations?

Do your treatment options change when faced with an adult patient with T2D who has heart failure, established atherosclerotic CVD, or CV risk factors but no established disease, like the majority of T2D patients?

Apart from checking that the anti-glycaemic medication you wish to prescribe is indicated for the prevention of major adverse cardiovascular events, what other prescribing factors do